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The homodimeric insulin and type 1 insulin-like
growth factor receptors (IR and IGF-1R) share a
common architecture and each can bind all three
ligands within the family: insulin and insulin-like
growth factors I and II (IGF-I and IFG-II). The receptor
monomers also assemble as heterodimers, the pri-
mary ligand-binding sites of which each comprise
the first leucine-rich repeat domain (L1) of one recep-
tor type and an a-chain C-terminal segment (aCT) of
the second receptor type. We present here crystal
structures of IGF-I bound to such a hybrid primary
binding site and of a ligand-free version of an IR
aCT peptide bound to an IR L1 plus cysteine-rich
domain construct (IR310.T). These structures, re-
fined at 3.0-A˚ resolution, prove congruent to res-
pective existing structures of insulin-complexed
IR310.T and the intact apo-IR ectodomain. As such,
they provide key missing links in the emerging, but
sparse, repertoire of structures defining the receptor
family.
INTRODUCTION
The human insulin receptor (IR) and human type 1 insulin-like
growth factor receptor (IGF-1R) are two closely related receptor
tyrosine kinases that play a role in regulating glucose homeosta-
sis and normal human growth, respectively (Adams et al., 2000;
Belfiore et al., 2009). Both receptors are disulfide-linked (ab)2 ho-
modimers and the degree of similarity between their respective
monomers is such that (1) they can form functional heterodimeric
hybrid receptors (Belfiore et al., 2009) and (2) all three ligands
within the family (insulin and insulin-like growth factors I and II
[IGF-I and IGF-II]) display affinity to both the homodimeric and
hybrid receptors (Denley et al., 2005), with the binding character-
istics of the hybrid receptors resembling IGF-1R not IR (Slaaby
et al., 2006). Aberrant signaling within this family is implicatedStructure 23, 1in diabetes (IR) (Boucher et al., 2014), cancer (IR, IGF-1R, and
their hybrids) (Pollak, 2012b), and Alzheimer’s disease (IR and
IGF-1R) (Steen et al., 2005). Of particular interest in the context
of cancer is the stimulation of cell growth upon IGF-II binding
to the A isoform of IR (IR-A) and/or to the hybrid IR-A/IGF-1R re-
ceptor (Belfiore et al., 2009); such binding is a possible escape
mechanism to therapeutic antibodies designed to inhibit IGF-
1R signaling (Pollak, 2012a).
Despite the physiological and therapeutic relevance of IR and
IGF-1R, structural understanding of the manner in which their
extracellular ectodomains bind ligand and effect specific sig-
nal transduction is only partially understood, due to both the
complexity of the conformational states involved and the con-
comitant paucity of structures that illuminate these (Table 1).
The current understanding is as follows (Ward et al., 2013).
Each receptor monomer consists (from its N terminus) of a
leucine-rich repeat domain (L1), a cysteine-rich domain (CR), a
second leucine-rich repeat domain (L2), followed by three type
III fibronectin domains (FnIII-1, FnIII-2, and FnIII-3). Within the
canonical CC0 loop of the FnIII-2 domain is a so-called insert
domain, a polypeptide segment of approximately 100 residues
that contains the proteolytic processing site that in turn
yields the a and b chains of the mature receptor monomer. In
the case of the IR homodimer, these domains arrange in a
two-fold symmetric, disulfide-linked L-shaped conformation
(McKern et al., 2006; Smith et al., 2010; Tulloch et al., 1999) (Fig-
ure 1A). The ectodomain of IGF-1R likely exhibits a similar
conformation (Tulloch et al., 1999;Whitten et al., 2009). Of funda-
mental importance to ligand binding is the C-terminal region
(aCT) of the receptor a chain (Kurose et al., 1994), which in
the case of IR has been shown to assemble in a predominantly
a-helical conformation on the central b-sheet (L1-b2) of the L1
domain of the opposite monomer (Smith et al., 2010). Together,
the aCT/L1 tandem element forms the primary insulin binding
site (site 1) on the receptor surface. Structural data indicate
that insulin binding to site 1 of IR involves at least the following
concerted conformational changes: (1) displacement of the
B-chain C-terminal segment of insulin away from the insulin he-
lical core, (2) rotation and re-modeling of the aCT segment upon
the surface of L1-b2, and (3) docking of the insulin B-chain helix
parallel to aCT, with aCT residues His710 and Phe714 engaging271–1282, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1271
Table 1. Crystal Structures of IR and IGF-1R Ectodomain Fragments and their Ligand Complexes
Receptor Constructa Fab Ligand Resolution (A˚) PDB
IR ectodomain homodimerb 23 (83-7 + 83-14) none 3.8 2DTGb
3.8 3LOHc
IR L1-CR-L2 none none 2.3 2HR7d
IGF-1R L1-CR-L2 none none 2.6 1IGRe
IR L1-CR + aCT704719 83-7 insulin 3.9 3W11f
3.3 4OGAg
IR L1-CR + aCT704719 83-7 [D-ProB26]-DTI-NH2 4.3 3W12
h
IR L1-CR + aCT697719 83-7 [D-ProB26]-DTI-NH2 4.3 3W13
f
IR [L1-CR-L2-(FnIII-1)-aCT704719]2 23 (83-14) insulin 4.4 3W14
f
Hybrid IR L1-CR + IGF-1R aCT691706 none IGF-I 3.0 4XSSh
IR L1-CR + aCT697719 none none 3.0 4XSTh
aResidue numbering of all IR aCT segments corresponds to that of the IR-A isoform.
bIRDb construct (McKern et al., 2006).
cSmith et al. (2010).
dLou et al. (2006).
eGarrett et al. (1998).
fMenting et al. (2013).
gMenting et al. (2014).
hThis work.the insulin core (Menting et al., 2013, 2014) (Figure 1B). The role
of aCT in this event is thus central, mediating a switching of the
hormone from its receptor-free to receptor-bound conformation
(Menting et al., 2014). The mode of interaction of the IGFs with
IGF-1R, IR-A, and the IR/IGF-1R hybrid receptors is likely similar
to that of insulin, although no structure currently exists for an IGF
in complex with either receptor or with their hybrids.
Three key but quite disparate classes of crystal structures
underpin the above understanding of conformational change
(Table1). Thefirst is the two-domain (L1-CR) IRconstruct comple-
mented with exogenous aCT peptide of IR-A (i.e., residues 704–
719) and complexed in turn with insulin (or insulin analog) and
the antigen-binding fragment (Fab) 83-7; IR L1-CR + IR aCT are
together termed the insulin microreceptor (mIR) (Menting et al.,
2013, 2014). Three such structures exist; in one, the mIR contains
the longer aCT peptide comprising IR-A residues 697–719 (Ment-
ing et al., 2013). The second class is the structure of the artificially
arranged and truncated IR [L1-CR-L2-(FnIII-1)-aCT]2 construct in
complex with bovine insulin and Fab 83-14 (Menting et al., 2013).
The third class is the structure of the apo-ectodomain of IR with
four attachedFabs (McKernet al., 2006;Smithetal., 2010).Allma-
jor crystal contacts in this structure are Fabmediated, with one of
the Fabs (83-14) known to be inhibitory to insulin binding in the
holo-receptor context (Soos et al., 1986).
While these structures have led to landmark advances in our
understanding of the structural biology of the IR family, two
important issues arise concerning their coherence. The first is
that while the structure of the insulin/IR site 1 complex is likely
recapitulated in the IGF-1R system, facile extrapolation ignores
the fundamental difference between insulin and the IGFs;
namely, that insulins are dual-chain molecules while the IGFs
are larger, single-chain molecules (Figures 1C and 1D). Indeed,
were IGFs to bind to site 1 in a similar fashion to that observed
for insulin, such binding would imply a curious threading of the
C-terminal residues of the receptor aCT segment through the1272 Structure 23, 1271–1282, July 7, 2015 ª2015 Elsevier Ltd All rigpolypeptide loop formed between the helical core of the IGF
and its interconnecting C domain (Figure 1C). The second issue
concerns the structure of the apo-IR ectodomain (Figure 1A). It is
possible that crystal lattice embedding and attachment of four
Fabsmay here have altered the conformation of the ectodomain,
given that the latter is conformationally (i.e., functionally) flexible
(Flo¨rke et al., 2001). In particular, it may have modulated the
conformation of the aCT segment upon the L1 domain surface,
given the relatively low affinity (3 mM) of their isolated interac-
tion (Menting et al., 2009). Such modulation would misinform
our understanding of conformational change in the site 1 tandem
element upon insulin binding, as receptor conformational
change upon ligand binding seen in the severely truncated mIR
(Figure 1B) is currently assessed relative to its conformation
within the structure of the Fab-complexed apo-IR ectodomain.
To resolve these issues, we present here two structures em-
ploying an endoglycosidase-treated IR L1-CR construct that
permits crystallization in the absence of attached Fab. The first
structure is that of a complex of the insulin receptor L1-CR frag-
ment, an IGF-1R aCT segment (residues 691–706, equivalent
to the IR-A aCT segment 704–719) and IGF-I. This structure pro-
vides the first view of an IGF bound to a receptor fragment of this
family, exemplifying the interaction of ligand with one of the two
distinct site 1 components of a hybrid IR/IGF-1R receptor
(Slaaby et al., 2006). The mode of interaction of the IGF with
the hybrid site 1 is seen to closely mimic that of insulin with IR
site 1. The second structure is that of an apo mIR (i.e., a complex
consisting solely of IR L1-CR + an extended IR-A aCT697719),
which provides a link between that of the Fab-complexed apo-
IR ectodomain (McKern et al., 2006; Smith et al., 2010) and the
insulin-complexed mIR (Menting et al., 2013, 2014). The disposi-
tion of the IR aCT peptide in this second structure is seen to
closely mimic that of the aCT segment in the intact IR ectodo-
main structure. The two structures thus deliver coherence to
the emerging picture of ligand binding within the IR family.hts reserved
Figure 1. Structural Biology of the Insulin Receptor Family
(A) Inverted L-conformation of the apo-IR ectodomain homodimer (structure PDB: 3LOH; Table 1). One monomer is shown in ribbon representation (cyan +
purple) with the respective domains labeled, the other in molecular surface representation (white + purple). From Menting et al. (2013).
(B) Mode of engagement of insulin with site 1 of the IR ectodomain (structure PDB: 4OGA; Table 1). The key structural transitions are highlighted and include the
re-orientation and remodeling of the aCT segment from its apo-conformation (translucent purple) to liganded conformation (solid purple) and a folding out of the
insulin B-chain C-terminal residues from the hormone core (receptor-free conformation, translucent black; receptor-bound conformation, black).
(C) Primary sequences of human insulin, IGF-I and IGF-II. The B and A chains of insulin and the B, C, A, and D domains of IGFs are indicated.
(D) Ribbon diagrams of insulin (PDB: 4INS), IGF-I (PDB: 1GZR) and IGF-II (PDB: 1GZL model 1). Insulin and IGF polypeptide segments are colored as indicated
in (B); the dashed segment indicates the disorder of part of the IGF-I C domain within PDB: 1GZR.RESULTS
Protein Production and Ligand Affinity Measurement
An SDS-PAGE analysis of endoglycosidase-treated IR310.T (eg-
IR310.T) is presented in Figure 2. IR310.T before endoglycosi-
dase treatment exhibited a major band at 51 kDa and a minor
band at 48 kDa; after endoglycosidase treatment it exhibited a
major band at46 kDa and aminor band at42 kDa. The limited
reduction inmolecular weight indicates that neither endoglycosi-
dase H nor endoglycosidase Hf treatment succeeded in trim-
ming all six of the N-linked glycans attached to IR310.T to single
N-acetylglucosamine species (Sparrow et al., 2008). The doublet
nature of the IR310.T protein has been reported previously
(Menting et al., 2013); we speculate here that it arises from differ-
ential glycosylation by the host cell (Sparrow et al., 2008).
Structure of the Hybrid mIR in Complex with IGF-I
The structure of the [IGF-I]-liganded hybrid mIR was determined
by molecular replacement; the initial search model was the IR
L1-CR fragment extracted from PDB: 3LOH (Table 1). Following
crystallographic refinement of this fragment within the asym-Structure 23, 1metric unit, inspection of a B-factor blurred (Fobs  Fcalc)-differ-
ence electron density map (Bblur = 50 A˚
2) revealed the presence
of a cluster of four helix-like features (Figure 3A) in a location
on the L1 domain surface equivalent to that of the respective
helices of IR-A aCT704719 and insulin in the structure of the
insulin-bound microreceptor (PDB: 4OGA; Table 1). A model of
IGF-1R aCT in the context of the IR310.T L1 domain was then
generated directly from that of IR aCT as seen in structure
PDB: 4OGA. The structure of IGF-I (PDB: 1GZR; Brzozowski
et al., 2002) was positioned in the asymmetric unit by molecular
replacement in the presence of the already placed IR L1-CR and
IGF-1R aCT moieties; this process placed IGF-I in the location
anticipated from the features in the blurred difference map
described above. The ternary complex was then subjected
to multiple rounds of crystallographic refinement and model
building, employing data to 3.0-A˚ resolution. Final refinement
statistics are presented in Table 2 with sample volumes of
(2Fobs  Fcalc)-difference electron density maps in Figure 4.
As anticipated from the initial difference map analysis (Fig-
ure 3A), the overall mode of assembly of the IGF-I/hybrid micro-
receptor complex is closely similar to that of the insulin/mIR271–1282, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1273
Figure 2. Coomassie-stained SDS-PAGE Gel Illustrating the Prepa-
ration of eg-IR310.T
Lane A,molecular weight markers; lane B, eg-IR310.T obtained upon digestion
of IR310.T with endoglycosidase H; lane C, IR310.T before digestion with
endoglycosidase H; lane D, SEC peak fraction corresponding to monomeric
eg-IR310.T obtained upon digestion of IR310.T with endoglycosidase H; lane
E, SEC peak fraction corresponding to aggregate eg-IR310.T obtained upon
digestion of IR310.T with endoglycosidase H; lane F, eg-IR310.T obtained
upon digestion of IR310.T with endoglycosidase Hf followed by SEC and
amylose resin affinity chromatography; lane G, IR310.T before digestion with
endoglycosidase Hf.complex (Figure 3B; Table 3).While no traceable electron density
was observed in the difference maps for residues 27–29 of the B
domain or residues 30–40 of the C domain of IGF-I, islands of
relatively high difference density were apparent in the volume
between modeled residues Asn26 and Thr41 that were consis-
tent with these missing residues being constrained to lie in
the immediate proximity of the L1-b2 surface. Further residues
that were omitted from the model due to being either poorly
ordered or ambiguous were (1) the two N-terminal and the seven
C-terminal (D domain) residues of IGF-I (residues 1–2 and 64–70,
respectively), (2) the C terminus of IR310.T (residue 310 and the
remaining residues of the thrombin cleavage motif; Menting
et al., 2013), and (3) the two N-terminal and two C-terminal
residues of IGF-1R aCT (residues 691–692 and 705–706,
respectively). Residues 265–275 of IR310.T appeared marginally
disordered but were nevertheless tentatively modeled. These
residues lie within the sixth disulfide-linked module of the CR
domain and form an extended loop adjacent to the L1-b2 sheet
surface and are also poorly ordered in all IR-based structures
determined to date (Table 1). This loop is understood to be ama-
jor determinant of ligand specificity (Hoyne et al., 2000) and one
of the major points of structural difference between IR and IGF-
1R L1-CR-L2 modules (Lou et al., 2006).
We turn now to a more detailed comparison of the respective
components of this structure with those of the insulin-bound mIR1274 Structure 23, 1271–1282, July 7, 2015 ª2015 Elsevier Ltd All rigstructure PDB: 4OGA (Table 1), taking into account the limited
resolution of the two structures.
The aCT Peptide
The mode of engagement of IGF-1R aCT with the IR L1 domain
is closely similar to that of IR aCT with the IR L1 domain in
structure PDB: 4OGA (Figure 5A); the most apparent differ-
ences are at sites of sequence disparity (i.e., at IGF-1R
Phe695, Ser699, and Ile700, equivalent to IR Tyr708, Val712,
and Val713, respectively). While the side chains of IGF-1R
Phe695 and IR Tyr708 appear to occupy the same location
on the L1 domain surface and exhibit similar rotameric confor-
mation, the conformation of the aromatic side chain of their in-
teracting L1 domain residue Phe89 differs in the two structures
(Figure 5B). As far as can be discerned, the side-chain hydroxyl
of IGF-1R Ser699 is directed away from the hydrophobic sur-
face of L1, whereas in the IR, the side chain of the equivalent
residue Val712 is directed toward the L1-b2 surface (Figure 5A).
Likewise, the Cd atom of IGF-1R Ile700 appears to be directed
into the L1-b2 surface; the side chain of this residue is larger
than that of its counterpart in IR (Val713) and accommodation
of the additional methylene group appears to be mediated by
rotameric re-arrangement of the side chain of the L1 domain
residue Leu62 (Figure 5B). Of the eight residues of IGF-1R
aCT that are judged to interact with IGF-1 (viz., Glu693,
Asn694, His697, Asn698, Ile700, Phe701, Val702, Pro703), all
except Asn694 and Ile700 are conserved in IR, wherein they
are replaced by Asp and Val, respectively (Figure 5A). Here,
the side chain of Asn694 lies in well-defined electron density
and is directed toward the Cys6-Cys48 disulfide bond of the
bound IGF-1 molecule, whereas in insulin-bound mIR (structure
PDB: 4OGA), the side chain of IR Asp707 appears to be
directed away from the bound insulin molecule. The interaction
of Ile700 with IGF-1 is solely backbone mediated. Finally, the
C-terminal residues of the IGF-1R aCT peptide, although not
conformationally well defined beyond residue 702, unequivo-
cally lie above the IGF-I B domain (Figure 5A), thus threading
through the polypeptide loop formed by the C domain of IGF-
I as it co-joins the B and A domains of the ligand.
The IGF-I Ligand
The aromatic triplet Phe23-Tyr24-Phe25 of the B domain of
IGF-1 adopts a similar conformation to that seen for the equiva-
lent insulin residues PheB24-PheB25-TyrB26 in the insulin-bound
mIR structure (Figure 5C). In particular, the side chain of the
critical residue Phe23 is directed into the overwhelmingly hydro-
phobic pocket formed by IR residues Asn15, Phe39, and Leu37,
IGF-1R aCT residue Phe701, and IGF-I residue Leu14. The side
chain of Tyr24 is directed away from the IR L1-b2 surface, posi-
tioned between IR residue Arg14 and IGF-I aCT residue Arg704.
The side chain of Phe25 appears to stack against the respective
carboxylate and guanidinium groups of IR residues Asp14 and
Arg16. The disposition of Phe23-Tyr24-Phe25 with respect to
the IGF-I helical core recapitulates the hinge-like displacement
of the B-chain C-terminal segment of insulin away from the
insulin core seen in the insulin-bound mIR structure PDB: 4OGA
(Table 1). As mentioned, no order is apparent beyond IGF-I res-
idue Asn26, again recapitulating the absence of order beyond
the insulin-equivalent residue ThrB27 in structure PDB: 4OGA.
Comparison of the mode of disposition of IGF-I on the mIR sur-
face with that of insulin reveals a closely similar pose. Of the sixhts reserved
Figure 3. Quaternary Structure of the Complex of eg-IR310.T, IGF-I, and IGF-1R aCT691–706
(A) B-factor blurred (Fobs Fcalc)-difference electron density map (Bblur = 50 A˚2) obtained after molecular replacement of the IR310.T fragment alone, showing the
correspondence of the location of tube-like electron density features with the location, on the L1 domain, of insulin and IR aCT in structure PDB: 4OGA (Table 1).
(B) Orthogonal views of the refined model of the eg-IR310.T, IGF-I and IGF-1R aCT691706 complex. The thinned tube (black/orange) indicates speculative
placement of IGF-I C domain residues 31–40 (see text). The sites of the pairs of arginine residues within the C domain of IGF-I and within the IR loop formed by
residues 266–274 are indicated by an asterisk and hash symbol, respectively. The coloring of the polypeptide segments of IGF-I is as per Figure 1C; the aCT
segment is in purple in both panels.
(C) Cartoon depiction of the proposed threaded topology of the IGF-I/hybrid microreceptor complex structure presented here.
(D) Cartoon depiction of an alternative non-threaded topology for the IGF-I/hybrid microreceptor. Such topology would likely incur significant steric clash.
(E) Cartoon depiction of a plausible non-threaded topology for an IGF bound to site 1 of IR-B. The path of IR-B aCT is highly speculative but does not thread
through the IGF C domain loop. In (C–E), the L1 surface is depicted in cyan and the IGF D domain is omitted for clarity.residues of IGF-I that are in contact with the IR L1 domain (viz.,
Val11, Asp12, Asp20, Gly22, Phe23, and Phe25; Figure 5C), all
are well conserved in human insulin (as ValB12, GluB13, GluB21,
GlyB23, PheB24, and TyrB26, respectively; Figure 1C). Similarly,
of the ten residues of IGF-I that are in contact with IGF-1R aCT
(viz., Gly7, Val11, Tyr24, Phe25, Gly42, Ile43, Val44, Asp45,
Met59, and Tyr60), all exceptMet59 arewell conserved in human
insulin (as GlyB8, ValB12, PheB25, TyrB26, GlyA1, IleA2, ValA3, GluA4,
and TyrA19, respectively); the insulin-equivalent of IGF-1Met59 is
AsnA18 (Figure 1C). An overlay of these IGF-I residues and their IR
counterparts in the context of the hybrid microreceptor structure
is shown in Figures 5C and 5D.
As mentioned earlier, absence from the difference electron
density maps is evidence of a disordered IGF-I C domain.
Nevertheless, we constructed, in a speculative fashion, a po-
tential path for the C domain that coincided as far as possible
with low-resolution features in the density map in the volume
between IGF-I residues Asn25 and Thr42. The path indicated
that the bulk of the C domain loop was likely positioned some-Structure 23, 1what away from the loop formed by the specificity-determining
IR residues 265–275 (Hoyne et al., 2000; Lou et al., 2006) (Fig-
ure 3B). Within this speculative model, the part of the IGF-I C
domain that contains residues Arg36 and Arg37 is distal to IR
Arg270 and Arg271.
The IR L1-CR Module
Of the L1 domain residues that are seen to engage either IGF-1R
aCT and/or IGF-I, differences with respect to the insulin-bound
mIR have already been noted at Leu62 and Phe89.
Inspection of difference electron density at the six N-glycosyl-
ation sites of IR310.T (Sparrow et al., 2008) allowed modeling of
one sugar residue at Asn16, four at Asn25, one at Asn111, one at
Asn215, three at Asn255, and one at Asn295. Some sugar-like
difference density extended beyond the single residuesmodeled
at Asn16 and Asn295, leading to the conclusion that only the car-
bohydrate at sites Asn111 and Asn215 were processed by the
endoglycosidase. This conclusion is consistent with the limited
reduction in the molecular weight of IR310.T upon endoglycosi-
dase treatment (Figure 2).271–1282, July 7, 2015 ª2015 Elsevier Ltd All rights reserved 1275
Table 2. X-Ray Diffraction Data Collection and Crystallographic
Refinement Statistics





Space group H32 P6322




No. of crystals 1 2
No. of complexes per
asymmetric unit
1 1
Resolution (A˚) 109.5–3.0 (3.1–3.0)a 100–3.0 (3.1–3.0)
Completeness (%) 99.7 (99.9) 99.9 (100.0)
Rmerge 0.13 (2.01) 0.50 (8.93)
b
<I/s(I)> 12.0 (0.9) 7.8 (0.6)
Redundancy 6.3 (6.2) 21.2 (21.2)
CC1/2
c 0.998 (0.441) 0.997 (0.265)
Refinement
Wilson B-factor (A˚2) 92 104
B11, B22, B33 (A˚
2) 18.9, 18.9, 37.8 8.5, 8.5, 17.0
Resolution range (A˚) 46.3–3.0 79.4–3.0








eg-IR310.T (protein) 122 112







% Favored 94.9 93.5
% Acceptable 4.7 3.8
% Outliers 1.4 2.7
aThe high R-factors reported here reflect both the high redundancy of the
dataset and the inclusion of weak data based on the CC1/2 statistic (see
footnotec).
bStatistics for the highest resolution shell are shown in parentheses.
cCC1/2, Pearson correlation coefficient between independently merged
halves of the dataset. In the highest resolution shell, the CC1/2 statistic
is significant at a level of probability of at least P = 0.001.
dautoBUSTER reports R-factors as R = <jFhxpct  Fhobsj>/<jFhobsj>,
where Fh
xpct is the expectation value of the model structure factor ampli-
tude. Free set is 5% of total number of reflections.Structure of Ligand-Free mIR
The structure of the ligand-free mIRwas determined bymolecular
replacement using diffraction data to a resolution of 3.0 A˚. The
initial search model comprised the IR L1-CR fragment from
PDB: 2HR7 (B protomer; Table 1). Following crystallographic
refinement of this module within the asymmetric unit, inspection1276 Structure 23, 1271–1282, July 7, 2015 ª2015 Elsevier Ltd All rigrevealed the presence of a helix-like feature in a B-factor blurred
(Fobs Fcalc)-difference electron density in a similar (although not
identical) location on the L1-b2 to that of the aCT component
within the structure of the apo-IR ectodomain (Smith et al.,
2010) (Figure 6A). Residues 698–713 were readily modeled into
the density, with the refined residues 698–710 in a helical confor-
mation consistent with that in the structure of the apo-IR ectodo-
main (Figures 6B and 6C). Critically, the additional helical turn
formed by IR aCT residues 711–714 in the insulin-complexed
mIR structures andwhich directs the side chain of Phe714 toward
the insulin core (Menting et al., 2013, 2014) is not observed in this
structure, consistent with its absence in the apo-IR ectodomain
structure (Smith et al., 2010). We note, however, that the confor-
mation of residues C-terminal to Asn711 are potentially influ-
enced by a two-fold related lattice partner (Figure 7A). The helix
formed by aCT residues 698–710 is rotated clockwise by
approximately 20 with respect to its counterpart in the apo-IR
ectodomain structure PDB: 3LOH (Smith et al., 2010); its orienta-
tion is thus intermediate to that observed in structure PDB: 3LOH
and to that observed in the insulin-complexed structures (PDB:
3W11, 3W12, 3W13, 3W14, and 4OGA), all of the latter exhibiting
a 54 rotation of aCT with respect to its apo-disposition in
structure PDB: 3LOH (Figure 7B) (Menting et al., 2013). However,
the change in disposition observed here with respect to the apo-
IR ectodomain is almost entirely rotational, without the concom-
itant translation along the L1-b2 surface observed in the insulin-
bound structures (Menting et al., 2013, 2014). Indeed, the aCT
helix is seen here to be anchored to the L1-b2 surface by the
side chains of aCT residues Phe701 and Phe705, which together
occupy the hydrophobic pocket formed by the side chains of L1
domain residues Leu62, Phe64, Phe88, Tyr91, Val94, Phe96, and
Glu120 (Figure 6D). These interactions are closely similar to
those observed in the apo-receptor structure (Figure 6E). The
side chain of residue Phe701 stacks against that of Arg118,
which in turn stacks against that of His144, similar to the
arrangement seen in the apo-receptor structure PDB: 3LOH.
Residue Leu709 appears displaced from the L1-b2 surface
compared with its counterpart in structure PDB: 3LOH, but
is otherwise similarly located. The side chain orientation of resi-
due Tyr708 is altered significantly with respect to its conforma-
tion in the apo-receptor (Figure 6E), suggesting that this residue
plays a limited role in defining the canonical interaction of the
aCT segment with the L1-b2 surface. However, the altered
conformation appears to be associated with a crystal contact,
wherein the side chain of residue Leu305 of a neighboring crys-
tallographic L1-CR domain (not shown) substitutes for that of
Tyr708.
A singleN-acetylglucosamine residue wasmodeled at each of
the N-linked sites Asn25, Asn111, Asn215, and Asn255, with that
at Asn255 having an attached fucose moiety. Difference density
suggestive of at least one sugar residue was apparent at Asn16,
as well as further carbohydrate-associated difference density at
residues 25 and 215, but none could be adequately modeled. No
glycan-like difference density was apparent at Asn295. These re-
sults are broadly consistent with the SDS-PAGE analysis (Fig-
ure 2) andwith the glycosylation analysis of the IGF-I-complexed
structure presented above, i.e. only limited endoglycosidase
processing has occurred. We note that the apparent absence
of extended carbohydrate features in the electron densityhts reserved
Figure 4. Stereo Images of Sample Differ-
ence Electron Density Corresponding to the
eg-IR310.T, IGF-I, and IGF-1R aCT691–706
Complex
(A) Map in the vicinity of IR L1 domain residues
34–38.
(B) Map in the vicinity of IGF-1R aCT residues
697–701.
(C) Map in the vicinity of IGF-I residues 23–25.
Selected residues in each panel are labeled. All
maps are of B-factor sharpened (2Fobs  Fcalc)-dif-
ference electron density (Bsharp = 50 A˚2), calcu-
lated after the final round of refinement.maps of the apo-mIR structure may also arise from the fact that
the diffraction dataset is a merge of that of two crystals (Table 2).
Finally, we note that in this structure, the loop formed by IR
residues 266–274, located in the specificity-determining sixth di-
sulfide-linked module of the CR domain (Hoyne et al., 2000; LouTable 3. Comparison of the Disposition of the IGF-1R aCT and
IGF-I on the IR L1 Domain Surface with Respect to their





Backbone Atoms rmsd (A˚)
IGF-1R 693–704
(aCT)
IR 706–717 55 0.82
IGF-I 6–25
(B domain)
insulin B7–B26 97 0.95
IGF-I 42–52
(A domain)
insulin A1–A21 104 1.20
The structure of the complex of IGF-I, IGF-1R aCT, and eg-IR310.T was
overlaid onto that of the insulin complex mIR (PDB: 4OGA) on the basis of
common L1 domain residues and the root-mean-square deviation (rmsd)
then computed across the common backbone atoms of the respective
aCT and IGF-I/insulin moieties. Backbone atoms are C, Ca, Cb, N, and
O; the computation utilized LSQMAN (Kleywegt and Jones, 1994).
Structure 23, 1271–1282, July 7, 2015et al., 2006), appears only partially or-
dered and has been left unmodeled.
DISCUSSION
The two structures presented here pro-
vide coherence to the limited and some-
what disparate repertoire of structures
that currently inform the structural biology
of IR family ectodomains (Table 1). First,
the structure of IGF-I in complex with the
L1-CR domains of IR and the IGF-1R
aCT peptide lends strong support to the
contention that IGFs bind, at least as far
as their site 1 interaction is concerned,
to their receptor in a similar fashion to
that observed in the insulin mIR com-
plexes. In particular, IGF-I is shown to un-
dergo a similar hinge-like opening of its B
domain away the growth factor core upon
receptor binding to that seen in the corre-sponding structures of insulin bound to IR site 1 (Menting et al.,
2013, 2014). Site 1 binding of IGF-I also results in a structural
re-arrangement of the aCT segment similar to that seen in the
structure of insulin bound to IR site 1, with the engagement of
the IGF-I B domain triplet Phe23-Tyr24-Phe25 with mIR closely
reflecting that of its insulin counterpart (Figure 5C). Second,
the structure of the apo-mIR provides a link between that of
the apo-IR ectodomain and the insulin-liganded mIRs and the
insulin-liganded IR593.aCT construct (Table 1). In particular,
the disposition of aCT upon the L1-b2 surface is effectively
conserved between these two apo-structures and is distinct
from that observed in the insulin-liganded structures. This obser-
vation implies that the disposition of the aCT segment in the apo-
IR ectodomain structure PDB: 3LOH has most likely not been
appreciably modulated by lattice embedding and/or by Fab
attachment, despite the segment’s relatively low affinity for the
IR L1 surface. Conversely, the apo-mIR structure provides further
credibility to the mIR-based insulin complexes, demonstrating
that the change in conformation seen in these latter structures
is not a consequence of domain minimization, but rather of insu-
lin binding.
In the IGF-I hybrid microreceptor complex presented here, the
IGF-I B domain residues Phe23-Tyr24-Phe25-Asn26 lie between
the IGF-1R aCTpeptide and the L1-b2 sheet of IR310.T (Figure 5).ª2015 Elsevier Ltd All rights reserved 1277
Figure 5. Comparison of the Structure of the Ternary Complex of eg-IR310.T, IGF-I, and IGF-1R aCT691–706 with that of Structure PDB: 4OGA
(Table 1)
(A) Overlay showing correspondence of IGF-1R aCT691706 (purple) and IR aCT704719 (white) on the surface of IR L1 (light cyan). Labels are provided for IGF-1R
aCT residues, labels for IR aCT equivalent residues are provided in parentheses where residues differ in type from their IGF-1R equivalents.
(B) Overlay showing differences, as far as can be discerned at the current resolution, in the conformation of L1 domain residues Leu62 and Phe89 as putative
consequences of the respective replacement of IR aCT Val713 by IGF-1R aCT Ile700 and of IR aCT Tyr708 by IGF-1R aCT Phe695. IR L1 domain residues are
shown in cyan in the case of the IGF-1R aCT/IGF-I complex and in white in the case of the IR aCT/insulin complex (structure PDB: 4OGA; Table 1). IGF-1R aCT is
shown in purple, IR aCT in light purple.
(C) Overlay showing correspondence of IGF-I B domain residues (black) with those of the insulin B chain (white) in their complex with eg-IR310.T (light cyan).
(D) Overlay showing correspondence of IGF-I A domain residues (yellow) with those of the insulin B chain (white) in their complex with eg-IR310.T (light cyan).
In all panels, thin tubes represent remaining ligand and/or aCT segments colored according to the same scheme.Residual difference electron density suggests that the IGF-I C
domain forms a direct connection to the A domain N terminus,
with the C-terminal region of the aCT peptide being threaded
through the loop formed by the C domain and the remainder of
IGF-I (Figures 3B and 3C). For completeness, however, we
need to consider an alternative indirect, non-threaded connec-
tion, wherein the polypeptide connecting IGF-I residues Asn27
to Thr41 executes a turn C-terminal to Asn27, then proceeds
approximately anti-parallel to IGF-I residues 23–27 along a
path between the aCT C-terminal region and the L1 domain of
IR310.T and then finally connects to IGF-I Thr41 via a path
approximately anti-parallel to the axes of the aCT helix and the
IGF-I B domain (Figure 3D). No evidence for such a path is
apparent in the residual difference electron density and such a
path would likely incur significant steric clash.
The B isoform of the human insulin receptor (IR-B) has an
approximately 3-fold lower affinity for IGFs compared with that1278 Structure 23, 1271–1282, July 7, 2015 ª2015 Elsevier Ltd All rigof IR-A (Denley et al., 2004). IR-B aCT is 12 residues longer
than that of IR-A and IGF-1R, the insert occurring between
IR-A residues 717 and 718. Secondary structure prediction
(data not shown) suggests that the inserted residues are devoid
of secondary structure. If, upon IGF binding, this longer IR-B aCT
segment were to thread through the C domain loop in a fashion
similar to that proposed for the IGF-bound structure presented
here (Figures 3B and 3C), there would most likely be a significant
reduction in the IGF on-rate compared with that of IGF binding to
IR-A. The observed (limited) reduction in affinity thus indicates a
commensurate reduction in off-rate. An alternative, perhaps
more likely, scenario is that the C-terminal region of the IR-B
aCT segment folds away from the bound IGF, leaving the C
domain free to adopt a direct path between domains B and A
(Figure 3E). There would hence be a fundamental difference in
the topology of the IGF IR-A and IR-B interactions. Interestingly,
IGF-1R proreceptors (wherein the aCT segment remainshts reserved
Figure 6. The aCT Segment within the apo-
mIR Structure
(A) (Fobs  Fcalc)-difference electron density map
(Bblur = 50 A˚
2) calculated after molecular replace-
ment/refinement of solely the IR310.T fragment
(cyan; fragment from structure PDB: 3W11).
(B) Topography of that component of the L2-b2
surface that engages the aCT segment.
(C) Stereo view of B-factor sharpened (2Fobs 
Fcalc)-difference electron density associated with
the aCT segment (Bsharp =60 A˚2), calculated after
the final round of refinement.
(D) Engagement of the aCT segment (purple) with
the L1 surface (cyan).
(E) Overlay showing the degree of conservation of
the rotamer conformation of aCT residues (labeled)
that engage the L1 surface in the apo-IR structure
PDB: 3LOH (white; Table 1) and in the apo-mIR
structure (purple) presented here.connected to the N terminus of the receptor b-chain) exhibit
reduced IGF-I binding and autophosphorylation and are likely
non-functional (Kawashima et al., 2005).
We have noted that the C domain of IGF-I directly juxtaposes
the extended loop formed by IR residues 265–274 but that the C
domain residues Arg34 and Arg35 are distal within the domain to
IR residues Arg270 and Arg271 (Figure 3B). Likewise, the IGF-I D
domain residues Lys65 and/or Lys68 (while disordered here)
also do not lie in the immediate vicinity of the IR residues
Arg270 and Arg271 (Figure 3B). We note further that the affinities
of IGF-II for both IR-A and IR-B are correspondingly higher than
affinities of IGF-I for IR-A and IR-B (Denley et al., 2004; Hender-
son et al., 2014), despite the additional two arginines in the C
domain of IGF-II with respect to that of IGF-I (Figure 1C). Lack
of electrostatic complementarity between IR and IGFs (Lou
et al., 2006) does not therefore appear to be the primary reason
for the reduced affinity of IGFs for IR, both with respect to that of
insulin for IR andwith respect to that of the IGFs for IGF-1R (Den-
ley et al., 2004). Instead, we propose that the higher affinity of
IGF-II for both IR-A and IR-B with respect to the corresponding
affinities of IGF-I to IR-A and IR-B (Denley et al., 2004; Hender-
son et al., 2014)may be attributable at least in part to the reduced
size of the IGF-II C domain with respect to that of IGF-I (Fig-
ure 1C), allowing easier steric accommodation within the volume
between the L1-b2 surface and that of the opposing CR domainStructure 23, 1271–1282, July 7, 2015of IR. However, our structure is unable to
reveal additional interaction(s) of bound
IGF with receptor domains absent from
the microreceptor construct and we thus
cannot rule out C domain sequence-spe-
cific modulation of IGF affinity within that
context (Henderson et al., 2014). Interest-
ingly, single-chain insulin/IGF C domain
hybrid ligands can bind both IR and IGF-
1R with high affinity (Kristensen et al.,
1995; Wang et al., 2000) and possess
ten times the growth-promoting activities
of insulin on a breast cancer cell line
(Wang et al., 2000).While the disposition of the aCT segment in the apo-mIR struc-
ture presented here is closely similar to that observed in the apo-
IR ectodomain structure PDB: 3LOH, it is not identical. There are
a number of possible reasons. The first is that there are no resi-
dues upstream of the aCT segment in the current structure, while
in the apo-IR ectodomain structure, tethering of upstream aCT
(i.e., the inter-a-chain disulfide(s) at the Cys682-Cys683-
Cys685 triplet) may restrain the aCT peptide from adopting
that seen in the apo-mIR structure presented here. The second
is that crystal contacts in the current structure may have modu-
lated the disposition of the aCT segment (Figure 7). The aCT
peptide has relatively low affinity (3 mM) for the L1 surface
(Menting et al., 2009); while this exceeds that of typical pro-
tein-protein crystal contacts, the difference is not sufficient to
rule out modulation by lattice embedding. The third is that there
is more than one conformation accessible by the aCT peptide
within the apo-receptor. Nevertheless, the key observation re-
mains that there is a common mode of engagement of aCT
with the L1-b2 surface via Phe701 and Phe705 in the apo-ecto-
domain and apo-mIR structures (Figure 6E) that is replacedwithin
the liganded structures by an alternative interaction mediated by
residues Phe705, Leu709, and Val713 (Menting et al., 2013).
Finally, our study provides strategies to expand the repertoire
of structures for the IR family. In particular, the resolution of
the two structures reported here is higher than most of thoseª2015 Elsevier Ltd All rights reserved 1279
Figure 7. Structural Biology of the apo-mIR
(A) Schematic diagram showing crystallographic neighbors (L1 domain, light orange; CR domain, light green; aCT segment, purple, labeled cryst.) surrounding
the aCT segment of the apo-mIR (L1 and CR domain, cyan; aCT segment, purple). Asterisk, site of interaction between a pair of neighboring aCT segments.
(B) Orthogonal views showing varying disposition of the aCT segment in apo- and insulin-complexed IR structures. Purple, aCT segment in the ligand-free mIR
structure presented here; white, aCT segment in the apo-IR ectodomain structure PDB: 3LOH (Table 1); and blue, aCT disposition in the insulin-complexed mIR
structure PDB: 4OGA (Table 1). Terminal residues of the respective aCT segments are labeled.recorded in Table 1, the exceptions being the respective unli-
ganded L1-CR-L2 structures of IR and IGF-1R (PDB: 2HR7
and 1IGR). This suggests that even limited removal of glycan
from receptor fragments can lead to improved resolution and
overcome the need for Fab complexation. Our study also dem-
onstrates the utility of the microreceptor construct for exploring
site 1 interactions within the broader insulin receptor family and
that its use should permit rapid progress to obtain structures of a
liganded IGF-1R site 1 and the liganded alternate hybrid receptor
IGF-1R L1-CR + IR aCT. Structural details of the interaction of in-
sulin and IGFs with the putative site 2 (De Meyts, 1994) of IR and
IGF-1R remain, however, elusive.
EXPERIMENTAL PROCEDURES
Production and Purification of Endoglycosidase-Treated IR310.T
Milligram quantities of the IR L1-CR construct IR310.T were prepared as
described previously (Menting et al., 2013). For the IGF-I + IGF-1R aCT com-
plex, IR310.T was incubated with endoglycosidase H (New England Biosci-
ences [NEB]) in G5 buffer (NEB) for 30 hr at 37C at a ratio of 1 mg of
IR310.T to 10,000 U of enzyme. Sample pH was immediately thereafter
adjusted by addition of 1/20th volume of 3 M Tris-HCl (pH 8.5). Monomeric
IR310.T was separated from aggregated forms and endoglycosidase H by
size-exclusion chromatography (SEC) on a Superdex S200 26/60 column (GE
Life Sciences) equilibrated with 24.8 mM Tris-HCl (pH 8.0), 137 mM NaCl,
2.7 mM KCl plus 0.02% NaN3 (TBSA). For the apo-mIR structure, IR310.T
was incubated with endoglycosidase Hf (endoglycosidase H fused to maltose
binding protein; NEB) in G5 buffer (NEB) for 5 hr at 37C at a ratio of 1 mg of
IR310.T to 20,000 U of enzyme. Sample pH was immediately thereafter
adjusted by addition of one-third volume of 103 TBS buffer (248 mM Tris-
HCl, 1.37MNaCl, 27mMKCl [pH 8.0]). SEC using a Superdex S200 26/60 col-
umn (GE Life Sciences) equilibrated with TBSA was employed to separate
monomeric from aggregated IR310.T and to remove endoglycosidase Hf. A
small quantity of enzyme remained in the IR310.T solution, despite attempts
to remove it by passage through an amylose resin affinity column (NEB).
Crystallization of the eg-IR310.T/IGF-1R aCT/IGF-I Complex
For crystallization, eg-IR310.T was prepared at 6 mg/ml in a 10 mM HEPES-
NaOH (pH 7.5) solution combined with a 1.5-fold molar ratio of IGF-1R
aCT691706 peptide (GenScript) and a 2-fold molar ratio of IGF-I (GroPep).
Following sparse-matrix screening at the CSIRO Collaborative Crystallization
Center (Parkville, Australia), optimized crystals of the complex were grown us-
ing hanging-drop vapor diffusion protocols in 1.75M ammonium sulfate, 0.1M
3-(cyclohexylamino)-1-propanesulfonic acid (CAPS)/NaOH (pH 10.5), 0.2 M1280 Structure 23, 1271–1282, July 7, 2015 ª2015 Elsevier Ltd All rigLiSO4, and 1:1 and 1:2 drop volume ratios. A single crystal was transferred
in a loop to 1.8 M (NH4)2SO4, 0.1 M CAPS-NaOH (pH 10.5), 0.2 M LiSO4 and
26% glycerol immediately prior to cryo-cooling by direct plunging into liquid
nitrogen. Diffraction data were collected at 100 K on beamline MX2 of the
Australian Synchrotron (McPhillips et al., 2002) and processed using XDS
(Kabsch, 2010). The resolution limit for data inclusion was set initially to be
2.7 A˚, the highest shell at which the CC1/2 statistic was significant at a level
of probability of at least P = 0.001 (Karplus and Diederichs, 2012) in order to
extract maximum information from weak data (Evans, 2012). However, during
the final stages of refinement this limit was reduced to 3.0 A˚ (Table 2).
Crystallization of mIR in Ligand-Free Form
Forcrystallization, eg-IR310.Twaspreparedat3.5mg/ml ina10mMHEPES (pH
7.5) solution combined with a 1.5-fold molar ratio of the 23-residue IR-A
aCT697719 peptide (GenScript). Following sparse-matrix screening at the
CSIROCollaborativeCrystallizationCenter (Parkville, Australia), optimized crys-
tals of the mIR were grown using hanging-drop vapor diffusion protocols with
reservoir solution 2.45M (NH4)2SO4+10%glycerol anda1:1drop ratio.Crystals
harvested in loopswere transferred to a solution containing 2.55M (NH4)2SO4 +
20% glycerol and then cryo-cooled by direct plunging into liquid nitrogen.
Diffraction data were collected at the Australian Synchrotron as described
above. Diffraction intensities from two crystals were combined to yield a single
high-redundancymergeddataset with statistics superior to those of the respec-
tive datasets from the individual crystals (Table 2). The resolution limit for data
inclusion was set as described above, i.e., at the highest shell at which the
CC1/2 statistic was significant at a level of probability of at least P = 0.001.
Structure Solution
Initial phases for both structureswere obtained bymolecular replacement using
PHASER (McCoy, 2007) with an IR L1-CR fragment employed as a search frag-
ment. Placement of the aCT segmentswas by direct differencemap inspection,
placement of IGF-I was by molecular replacement. Initial crystallographic
refinement employed PHENIX (Adams et al., 2002), which was followed by
extensive refinement with autoBUSTER (Bricogne et al., 2011) iterated with
manualmodel building with COOT (Emsley andCowtan, 2004). Final refinement
stages included (1) TLS refinement, (2) least-squares similarity restraints of eg-
IR310.T to structure PDB: 2HR7 (monomer A) and, in the case of the IGF-I com-
plex, to a higher resolution structure of IGF-I (PDB: 1GZR; Brzozowski et al.,
2002), and (3) allowance for missing atoms (Blanc et al., 2004).
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